210 related articles for article (PubMed ID: 9199241)
21. Cloning and characterization of human urocortin.
Donaldson CJ; Sutton SW; Perrin MH; Corrigan AZ; Lewis KA; Rivier JE; Vaughan JM; Vale WW
Endocrinology; 1996 May; 137(5):2167-70. PubMed ID: 8612563
[TBL] [Abstract][Full Text] [Related]
22. Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin.
Gottowik J; Goetschy V; Henriot S; Kitas E; Fluhman B; Clerc RG; Moreau JL; Monsma FJ; Kilpatrick GJ
Neuropharmacology; 1997 Oct; 36(10):1439-46. PubMed ID: 9423932
[TBL] [Abstract][Full Text] [Related]
23. Distribution of corticotropin-releasing factor (CRF) receptor binding in the mouse brain using a new, high-affinity radioligand, [
Tan LA; Vaughan JM; Perrin MH; Rivier JE; Sawchenko PE
J Comp Neurol; 2017 Dec; 525(18):3840-3864. PubMed ID: 28842924
[TBL] [Abstract][Full Text] [Related]
24. Urocortins of the South African clawed frog, Xenopus laevis: conservation of structure and function in tetrapod evolution.
Boorse GC; Crespi EJ; Dautzenberg FM; Denver RJ
Endocrinology; 2005 Nov; 146(11):4851-60. PubMed ID: 16037378
[TBL] [Abstract][Full Text] [Related]
25. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor.
Vaughan J; Donaldson C; Bittencourt J; Perrin MH; Lewis K; Sutton S; Chan R; Turnbull AV; Lovejoy D; Rivier C
Nature; 1995 Nov; 378(6554):287-92. PubMed ID: 7477349
[TBL] [Abstract][Full Text] [Related]
26. Development of a selective photoactivatable antagonist for corticotropin-releasing factor receptor, type 2 (CRF2).
Bonk I; Rühmann A
Eur J Biochem; 2002 Nov; 269(21):5288-94. PubMed ID: 12392562
[TBL] [Abstract][Full Text] [Related]
27. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
Gkountelias K; Tselios T; Venihaki M; Deraos G; Lazaridis I; Rassouli O; Gravanis A; Liapakis G
Mol Pharmacol; 2009 Apr; 75(4):793-800. PubMed ID: 19124613
[TBL] [Abstract][Full Text] [Related]
28. Characterisation using microphysiometry of CRF receptor pharmacology.
Smart D; Coppell A; Rossant C; Hall M; McKnight AT
Eur J Pharmacol; 1999 Aug; 379(2-3):229-35. PubMed ID: 10497910
[TBL] [Abstract][Full Text] [Related]
29. Cloning and characterization of corticotropin-releasing factor and urocortin in Syrian hamster (Mesocricetus auratus).
Robinson BM; Tellam DJ; Smart D; Mohammad YN; Brennand J; Rivier JE; Lovejoy DA
Peptides; 1999; 20(10):1177-85. PubMed ID: 10573289
[TBL] [Abstract][Full Text] [Related]
30. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists.
Eckart K; Jahn O; Radulovic J; Tezval H; van Werven L; Spiess J
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11142-7. PubMed ID: 11572971
[TBL] [Abstract][Full Text] [Related]
31. Differential responsiveness of CRF receptor subtypes to N-terminal truncation of peptidic ligands.
Brauns O; Brauns S; Zimmermann B; Jahn O; Spiess J
Peptides; 2002 May; 23(5):881-8. PubMed ID: 12084518
[TBL] [Abstract][Full Text] [Related]
32. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain.
Chang CP; Pearse RV; O'Connell S; Rosenfeld MG
Neuron; 1993 Dec; 11(6):1187-95. PubMed ID: 8274282
[TBL] [Abstract][Full Text] [Related]
33. Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site.
Dautzenberg FM; Wille S; Lohmann R; Spiess J
Proc Natl Acad Sci U S A; 1998 Apr; 95(9):4941-6. PubMed ID: 9560207
[TBL] [Abstract][Full Text] [Related]
34. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle.
Kishimoto T; Pearse RV; Lin CR; Rosenfeld MG
Proc Natl Acad Sci U S A; 1995 Feb; 92(4):1108-12. PubMed ID: 7755719
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.
Perrin MH; Tan LA; Vaughan JM; Lewis KA; Donaldson CJ; Miller C; Erchegyi J; Rivier JE; Sawchenko PE
J Pharmacol Exp Ther; 2015 May; 353(2):307-17. PubMed ID: 25736419
[TBL] [Abstract][Full Text] [Related]
36. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
37. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
Beyermann M; Heinrich N; Fechner K; Furkert J; Zhang W; Kraetke O; Bienert M; Berger H
Br J Pharmacol; 2007 Jul; 151(6):851-9. PubMed ID: 17533422
[TBL] [Abstract][Full Text] [Related]
38. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid.
Liaw CW; Lovenberg TW; Barry G; Oltersdorf T; Grigoriadis DE; de Souza EB
Endocrinology; 1996 Jan; 137(1):72-7. PubMed ID: 8536644
[TBL] [Abstract][Full Text] [Related]
39. Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment.
Hauger RL; Olivares-Reyes JA; Braun S; Hernandez-Aranda J; Hudson CC; Gutknecht E; Dautzenberg FM; Oakley RH
Regul Pept; 2013 Sep; 186():62-76. PubMed ID: 23820308
[TBL] [Abstract][Full Text] [Related]
40. Corticotropin releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes.
Slominski AT; Roloff B; Zbytek B; Wei ET; Fechner K; Curry J; Wortsman J
In Vitro Cell Dev Biol Anim; 2000 Mar; 36(3):211-6. PubMed ID: 10777063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
